



08/27/07

1FW

Dkt. No. 29248/18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Erik Buntinx
Appl. No. : 10/725,965
Filed : December 2, 2003
For : METHOD OF TREATING MENTAL DISORDERS USING
OF D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS
OR PARTIAL AGONISTS
Art Unit : 1617
Examiner : Umamaheswari Ramachandran
Customer No.: 1912

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

"Express Mail" mailing label No. EV 725836748 US
Date of Deposit: August 24, 2007

I hereby certify that this paper or fee is being
deposited with the United States Postal Service
"Express Mail" service under 37 CFR 1.10 on the date
indicated above and is addressed to the
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450.

Name: Alan D. Miller

Signature: [Signature]

Sir:

This Supplemental Information Disclosure Statement (SIDS) is being filed
to supplement the Information Disclosure Statement filed on April 10, 2007 and
August 9, 2005 in connection with the subject application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant
would like to direct the Examiner's attention to the references that are listed on the
attached form PTO/SB/08A-B. A copy of each non-U.S. patent documents is also
attached. These references were cited in an Office Action issued on August 10, 2007 in

Applicant: Erik Buntinx
Serial No.: 10/725,965
Filed: December 2, 2003
Page 2


connection with U.S. Patent Application No. 10/984,683 and an Office Action issued on May 3, 2007 in connection with U.S. Patent Application No. 10/803,793.

Applicant is submitting the subject Supplemental Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required in connection with this submission or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: August 24, 2007
New York, New York

By 
Alan D. Miller, Reg. No. 42,889

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/725,965		
		Filing Date	December 2, 2003		
		First Named Inventor	Erik Buntinx		
		Art Unit	1617		
		Examiner Name	Umamaheswari Ramachandran		
Sheet	2	of	2	Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	HUBBLE J P et al., entitled "Pre-clinical studies of pramipexole: clinical relevance," European Journal of Neurology Supplement, 2000, Vol. 7 (Suppl. 1), pp. 15-20.	
	5	SILVER D E et al., entitled "Initiating therapy for Parkinson's disease," Neurology, 1998, Vol. 50 (Suppl. 6), pp. S18-S22.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.